10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors
1 other identifier
observational
1,114
1 country
27
Brief Summary
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2009
Shorter than P25 for all trials
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 21, 2009
CompletedFirst Posted
Study publicly available on registry
April 22, 2009
CompletedStudy Start
First participant enrolled
May 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedJune 29, 2010
June 1, 2010
10 months
April 21, 2009
June 28, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.
1 visit
Secondary Outcomes (3)
To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer
1 Visit
To analyse CHD management patterns according to defined 10-year CHD risk categories
1 Visit
To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk
1 Visit
Eligibility Criteria
Postmenopausal patients with early breast cancer, who are taking aromatase inhibitors no longer than 6 months as an adjuvant treatment after surgery
You may qualify if:
- Early Breast Cancer patients
- Postmenopausal Status
- patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months
You may not qualify if:
- Advanced Breast Cancer patients(stage iii, iv)
- Patients who are hard to be analysed by limitation of chart record according to investigators discretion
- patients who already have been registered in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (27)
Research Site
Cheonan, Chungcheongnam-do, South Korea
Research Site
Chuncheon, Gangwon-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Seongnam-si, Gyeonggi-do, South Korea
Research Site
Pohang, Gyeongsangbuk-do, South Korea
Research Site
Masan-si, Gyeongsangnam-do, South Korea
Research Site
Anyang, South Korea
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Gangneung, South Korea
Research Site
GuangJu, South Korea
Research Site
Gwangju, South Korea
Research Site
Incheon, South Korea
Research Site
Inchon, South Korea
Research Site
Jeonju, South Korea
Research Site
Junam, South Korea
Research Site
Koyang, South Korea
Research Site
Kyunggi, South Korea
Research Site
Pusan, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul(Kangbuk), South Korea
Research Site
Seoul(Kangdong), South Korea
Research Site
Seoul(Kangnam), South Korea
Research Site
Seoul(Yeouido), South Korea
Research Site
Suwon, South Korea
Research Site
Ulsan, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
JoonWoo Bahn, MD, PhD
AstraZeneca Korea
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 21, 2009
First Posted
April 22, 2009
Study Start
May 1, 2009
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
June 29, 2010
Record last verified: 2010-06